We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Management of Metastatic Castration-Resistant Prostate Cancer.
- Authors
Mukherji, Deborah; Eichholz, Andrew; De Bono, Johann S.
- Abstract
Metastatic prostate cancer remains a considerable therapeutic challenge; however, advances in clinical research have resulted in five new treatments in the last 2 years. The immunotherapy sipuleucel-T, the cytotoxic cabazitaxel, the androgen biosynthesis inhibitor abiraterone acetate, the radioisotope al- pharadin and the anti-androgen MDV3100 have all been shown to improve overall survival in randomized phase III studies for patients with metastatic castration-resistant prostate cancer. The therapeutic strategies of targeting androgen-receptor signalling and other key intracellular pathways involved in tumour progression and treatment resistance are yielding promising results. Agents such as the dual vascular endothelial growth factor receptor/ MET inhibitor cabozantinib, the clusterin inhibitor custirsen and the Src inhibitor dasatinib have shown encouraging results in phase II studies. Novel immunotherapeutics such as prostate-specific membrane antigen-directed therapy and the anti-cytotoxic T lymphocyte-associated receptor 4 (CTLA4) antibody ipilimumab are also under investigation. Optimal methods of treatment selection, combination and sequencing have yet to be determined.
- Subjects
ANTIANDROGENS; AMERICAN Society of Clinical Oncology; CANCER chemotherapy; DATABASES; IMMUNOTHERAPY; MEDLINE; META-analysis; METASTASIS; ONLINE information services; HEALTH outcome assessment; PROSTATE tumors; SOCIAL services case management; TREATMENT effectiveness; THERAPEUTICS
- Publication
Drugs, 2012, Vol 72, Issue 8, p1011
- ISSN
0012-6667
- Publication type
Journal Article
- DOI
10.2165/11633360-000000000-00000